by François Briand | Feb 27, 2023 | 2022
Physiogenex will be presenting its innovative obese NASH hamster model at the Global NASH Congress, London, UK, March 2nd-3rd, 2023. This unique preclinical model will be presented on poster#4 during each refreshment break and the networking reception on March the 2nd...
by François Briand | Dec 27, 2022 | 2022
Physiogenex is delighted to be awarded ISO 9001:2015, a globally recognized certification of quality management system standards. Our scope of certification « Preclinical research in pharmacology » includes in vivo and ex vivo CRO services delivered by Physiogenex....
by François Briand | Nov 29, 2022 | 2022
Physiogenex will be presenting its innovative obese NASH hamster model at the 20th World Congress of Insulin resistance, Los Angeles, CA, USA, Dec.1-3, 2022. The abstract entitled “Empagliflozin improves heart failure with preserved ejection fraction despite...
by François Briand | Nov 22, 2022 | 2022
Physiogenex will be presenting its innovative obese MetALD hamster model at the 7th Obesity and NASH Summit in Boston, MA, USA, Nov. 27-29, 2023. This unique preclinical model will be presented during the poster session on November the 28th at 2:30pm by Dr. François...
by François Briand | Nov 9, 2022 | 2022
Physiogenex will be presenting its innovative obese NASH hamster model at the AFDD (AntiFibrotic Drug Development) Summit in Boston, MA, USA, Nov. 10-11th, 2022. This unique preclinical model will be presented during an oral presentation and the poster session on...
by François Briand | Oct 28, 2022 | 2022
Physiogenex will be presenting 2 novel studies in its innovative obese NASH hamster model at the AASLD Liver Meeting in Washington D.C., USA, Nov. 4-8th, 2022. Studies will be presented during the poster session of Saturday November the 5th, posters #2318 and #2490....
